Riyadh - Mubasher: Middle East Pharmaceutical Industries Company (Avalon Pharma) named Ahmad Shaher Al Tabbaa as the board’s Chairman for the next four years.
The ordinary general meeting (OGM), which was held on 9 April 2026, also resolved to appointing Hisham Mohammed Attar as the Vice Chairman, according to a bourse statement.
Al Tabbaa and Attar will remain in their positions for the board term that started on 16 April 2026 and will end on 5 April 2030.
In April 2026, the Capital Market Authority (CMA) approved Avalon Pharma’s capital increase to SAR 350 million from SAR 200 million.
Earlier this year, the Saudi company signed a strategic commercialization agreement with Bio-Thera Solutions to support the registration of Pembrolizumab in Saudi Arabia and across MENA markets.
